Oncology Pharmacists Connect: 2025 agenda features a comprehensive lineup of sessions designed to enhance your knowledge and practice in oncology pharmacy. Building on the success of 2024, the 2025 event will include:
- Expert-Led Discussions: Engage with leading experts in oncology pharmacy through panel discussions and Q&A sessions that will provide deeper insights into clinical, operational, and financial analysis of trial updates and patient care strategies, directly informed by the 2025 ASCO Annual Meeting.
- Networking Opportunities: Connect with peers, researchers, and industry leaders to exchange ideas, discuss challenges, and forge collaborations that will advance your practice in the field of oncology pharmacy.
New Ways to Connect in 2025:
- Poster Session: Showcase your clinical and practice management research or explore the latest advancements in oncology pharmacy during the networking reception. See poster session tab for more details on submitting an abstract.
- Interactive Workshops: Enhance your professional development and problem-solving skills with actionable strategies to resolve challenges in oncology pharmacy.

Overview:
The complexity of new regimens and the need for coordination of care across practice and pharmacy settings has reinforced and expanded the roles of oncology pharmacists. This conference is designed for oncology pharmacists to meet as a larger ecosystem of pharmacists working together to identify and develop solutions for responding clinically and operationally to rapidly evolving evidence reported at the 2025 ASCO Annual Meeting. The program agenda facilitates bringing pharmacists focused on cancer care from multiple types of practice settings together to discuss recently presented data, identify resources needed to successfully implement new therapies and make formulary decisions, examine challenges, and brainstorm solutions to meet organizational demands while improving patient outcomes. The core meeting will be composed of accredited continuing education sessions, highlighting the most impactful ASCO abstracts from each disease state delivered as panel discussions to enable debate, discussion, and collaborative peer-exchange.
Core sessions include: hematologic malignancies, multiple myeloma, leukemia/lymphoma, genitourinary, gastrointestinal, cutaneous, thoracic, and breast cancers as well as delivery and quality of oncology care.
- Analyze recent clinical updates on novel and emerging pharmacotherapeutic approaches for solid and hematologic malignancies presented at the 2025 American Society of Clinical Oncology Annual Meeting.
- Explain the impact of recent evidence to multiple disease treatment paradigms and challenges to implementation of evolving therapies.
- Apply operational and managed care considerations for the evaluation and integration of changes through formulary decisions, pathways, and resource allocation.
Become part of the oncology pharmacy thread that connects people together to fight cancer. Join us at OPC this summer and continue building your oncology pharmacy connections!

Ryan Haumschild, PharmD, MS, MBA, CPEL
Director of Pharmacy Services
Emory Healthcare and Winship Cancer Institute
Atlanta, Georgia

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Clinical Pharmacy Manager, Hematology/BMT/Cellular Therapeutics
University of Kansas Health System
Kansas City, Kansas
Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Pharmacists at the Forefront: Enhancing Immunotherapy Strategies in Endometrial Cancer
Date: June 19, 2025
Time: 7:00 AM CDT – 8:00 AM CDT
Location: Virtual
Advances in Castration-Sensitive Prostate Cancer: A Pharmacist’s Approach to Optimize Novel Antiandrogen Therapies
Date: June 19, 2025
Time: 1:00 PM CDT – 2:00 PM CDT
Location: Virtual
Personalizing Treatment in Relapsed/Refractory Multiple Myeloma: The Evolving Role of Antibody-Drug Conjugates and Bispecific Antibodies
Date: June 20, 2025
Time: 10:30 AM CDT – 11:30 AM CDT
Location: Virtual




